Vaccine compositions and their uses
A fusion protein combining SARS-CoV-2 nucleocapsid N antigen with a self-assembling polypeptide and carrier protein, produced in a bacterial system, addresses the challenge of viral immune escape by providing broad-spectrum protection against coronavirus strains, including severe COVID-19, through enhanced immunogenicity and cross-reactive immune responses.
Patent Information
- Application Number
- JP2024537464
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-07-22
- Filing Date
- 2022-12-16
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current coronavirus vaccines primarily targeting the spike protein face challenges with viral immune escape due to multiple mutations, necessitating the development of vaccines that provide broad-spectrum protection, particularly against severe COVID-19.
A fusion protein comprising a nucleocapsid N antigen from SARS-CoV-2, a self-assembling polypeptide derived from a C4bp oligomerization domain, and a carrier protein with a positively charged tail, produced in a bacterial expression system, enhances immunogenicity and provides cross-protection against various coronavirus strains.
The fusion protein induces significant immune responses, including N-specific T cell and antibody responses, effectively protecting against severe COVID-19 and cross-protecting against different coronavirus strains, as demonstrated in hamster challenge models.
Smart Images

Figure 2024545462000020 
Figure 2024545462000021 
Figure 2024545462000022
Abstract
Description
[Technical field]
[0001] The present disclosure relates to immunogenic compositions and their use as vaccines for the prevention of coronavirus disease in human subjects.
[0002] [Background technology] At the end of 2021, the global pandemic of coronavirus disease 2019, caused by the emerging severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has resulted in more than 260 million cases with more than 5.2 million deaths worldwide. While some infected individuals remain asymptomatic, some develop a mild respiratory illness that recovers with little or no treatment, and others (10-20% of those who are symptomatic) experience severe illness, which often occurs as a sudden deterioration approximately 11 days after the onset of the first symptoms (Chen, S. et al., 2020. Front. Med. 0. doi:10.3389 / fmed.2020.567296), with respiratory failure and multi-organ complications that may occasionally cause the patient's death ("Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)". US Centers for Disease Control and Prevention (CDC). April 6, 2020. Archived from the original on March 2, 2020; updated February 12, 2021).
[0003] To date, vaccine development efforts have primarily targeted the spike (S) protein as the primary antigen, but concerns exist regarding "viral immune escape" as multiple mutations allow mutated viral strains to escape immunity against the S protein. The nucleocapsid (N protein) is relatively conserved among coronavirus variants during transmission and evolution.
[0004] Based on publicly available data as of the end of 2021, particularly from the WHO, regarding ongoing research and development efforts to develop a COVID vaccine, there are currently approximately 25 programs targeting the nucleocapsid.
[0005] Of these programs, the majority target epitopes, and only eight programs contain full-length nucleocapsid antigens (two DNA vaccines and three viral vector vaccines in clinical phase / one bacterial vector vaccine and two viral vector vaccines in preclinical phase), as briefly described below.
[0006] Clinical stage projects: Genexine is currently developing GX-19N, a DNA vaccine in phase 2 that encodes the SARS-CoV-2 receptor binding domain (RBD) foldon and nucleocapsid protein (NP) as well as plasmid DNA encoding the SARS-CoV-2 spike protein (Ahn et al., 2021, https: / / doi.org / 10.1101 / 2021.05.26.21257700).
[0007] Scancell is developing a bivalent DNA vaccine encoding both the spike protein receptor-binding domain and the full-length nucleocapsid protein of SA.RS-CoV-2 (Brentville et al., 2021, https: / / doi.org / 10.1101 / 2021.06.18.448932).
[0008] Vaxart is developing an oral tablet-based viral vector (Ad5) vaccine expressing full-length S and N antigens (presented at the Vaccine Conference in May 2021: https: / / investors.vaxart.com / static-files / b555c11c-6863-4763-8539-12754840a652).
[0009] City of Hope is developing a synthetic modified vaccinia Ankara (sMVA) vector that co-expresses the full-length SARS-CoV-2 spike and nucleocapsid (Chiuppesi et al., 2020, https: / / doi.org / 10.1038 / s41467-020-19819-1).
[0010] ImmunityBio is developing a viral vector vaccine using the human adenovirus serotype 5 (hAd5) platform that expresses both a spike (S) protein modified for increased cell surface expression (S fusion) and a nucleocapsid (N) protein with an enhanced T cell stimulatory domain (N-ETSD) to enhance MHC class I and II presentation and T cell responses (Sieling et al., June 2021, https: / / doi.org / 10.1101 / 2021.04.05.21254940; Rice et al., July 2021, https: / / pubmed.ncbi.nlm.nih.gov / 34290317 / ).
[0011] Preclinical projects: Colorado State University is developing a replicating bacterial vector vaccine expressing SARS-CoV-2 membrane and nucleocapsid proteins that demonstrated protection against severe COVID-19-like disease in hamsters (Jia et al., 2021, https: / / doi.org / 10.1038 / s41541-021-00321-8).
[0012] The University of Minnesota reported that HAd5 expressing the nucleocapsid (N) protein reduced weight loss and reduced viral load in both Syrian hamsters and k18-hACE2 mice (Matchett et al., https: / / doi.org / 10.1101 / 2021.04.26.441518).
[0013] Northwestern University Feinberg School of Medicine reported that an Ad5 vectored vaccine expressing the SARS-CoV-2 spike and nucleocapsid proteins could confer acute protection in both the lungs and brain (Dangi et al., 2021, https: / / doi.org / 10.1016 / j.celrep.2021.109664).
[0014] Despite these developments, there remains a need to further develop novel coronavirus vaccines, particularly vaccines that can confer broad-spectrum protection.
[0015] OVX836 (OSIVAX, Lyon, France) is a recombinant protein in clinical development as a vaccine against influenza strains. The antigenic portion corresponds to the NP sequence of the A / WSN / 1933 (H1N1) influenza virus. The OVX836 protein contains seven copies of NP, each fused to OVX313. The OVX313 sequence is derived from the C-terminal oligomerization domain of the human C4b-binding protein (hC4BP) [Hofmeyer T et al., J Mol Biol. 2013;425:1302-1317] but has been modified to minimize homology with the human sequence (hybrid chicken sequence; less than 20% homology).
[0016] The inventors have now surprisingly found that similar fusion proteins with the nucleocapsid N protein of the SARS-Cov2 strain can be efficiently produced, particularly in bacterial cell expression systems, and confer significant protection against coronavirus diseases, such as SARS-Cov2 disease, including cross-protection against different coronavirus strains (broad spectrum), as revealed, particularly in hamster studies.
[0017] [Brief Description] Thus, in one aspect, the disclosure provides an immunogenic composition for use as a vaccine for the prevention of a coronavirus disease, particularly COVID-19, typically for protection against severe COVID-19, in a human subject in need thereof, said immunogenic composition comprising a fusion protein, said fusion protein comprising: (i) a nucleocapsid N antigen, preferably a SARS-Cov2 N antigen, to which it is fused (ii) a carrier protein comprising a self-assembling polypeptide derived from the C4bp oligomerization domain and a positively charged tail; The present invention relates to an immunogenic composition comprising:
[0018] The disclosure also provides a method for preventing, protecting against, or cross-protecting against a coronavirus disease, particularly COVID-19, typically for protecting against severe COVID-19, to a human subject in need thereof, the method comprising administering an immunogenic amount of a fusion protein, the fusion protein comprising: (i) a nucleocapsid N antigen, preferably a SARS-Cov2 N antigen, to which it is fused (ii) a carrier protein comprising a self-assembling polypeptide derived from the C4bp oligomerization domain and a positively charged tail; The present invention relates to a method comprising the steps of:
[0019] The disclosure further relates to the use of the fusion protein in the manufacture of a vaccine for preventing, protecting against, or cross-protecting against a coronavirus disease, in particular COVID-19, typically for protecting against severe COVID-19, the fusion protein comprising: (i) a nucleocapsid N antigen, preferably a SARS-Cov2 N antigen, to which it is fused (ii) a carrier protein comprising a self-assembling polypeptide derived from the C4bp oligomerization domain and a positively charged tail; Includes.
[0020] In a preferred embodiment of said method or use, said fusion is OVX033 as disclosed hereinafter. In a further preferred embodiment, said fusion protein is formulated as an immunogenic composition for intramuscular administration and administered intramuscularly.
[0021] Another aspect of the present disclosure is a method for producing a method for manufacturing a semiconductor device comprising the steps of: (i) The SARS-Cov2 nucleocapsid N antigen and the (ii) a carrier protein comprising a self-assembling polypeptide derived from the C4bp oligomerization domain and a positively charged tail; The present invention relates to a fusion protein comprising:
[0022] In a specific embodiment, the fusion protein is non-glycosylated and / or obtainable from a bacterial expression system, such as an E. coli expression system. In a preferred embodiment, the fusion protein is OVX033, encoded by SEQ ID NO:11.
[0023] Another aspect of the disclosure relates to a nucleic acid encoding said fusion protein, in particular the nucleic acid of SEQ ID NO:11, or an expression vector comprising the nucleic acid of SEQ ID NO:11, or a host cell, typically a bacterial host cell, comprising the nucleic acid of SEQ ID NO:11. [Brief description of the drawings]
[0024] [Figure 1] SDS PAGE and Western blot analysis of OVX030. Purified OXV030 was fractionated on 4-12% Bis-Tris electrophoresis gels under reducing and denaturing conditions and stained with Instant Blue [A] or blotted onto nitrocellulose membranes and probed with polyclonal rabbit anti-OVX313 [B] and anti-nucleocapsid antibodies (Genetex, GTX135357) [C] followed by secondary anti-rabbit / HRP antibodies (Sigma, A0545). SDS PAGE: 0.5, 1, 1.5 μg / well. Western blot: 150, 300, 600 ng / well. MW: molecular weight markers. [Diagram 2]Overexpression analysis of synthetic DNA constructs of N-OVX313 protein by SDS PAGE (A) and Western blot (B). Total fraction extracts (normalized samples) were fractionated on 4-12% Bis-Tris electrophoresis gels under reducing and denaturing conditions and stained with Instant Blue (A) or blotted onto nitrocellulose membranes and probed with an anti-nucleocapsid antibody (Genetex, GTX135357) followed by a secondary anti-rabbit / HRP antibody (Sigma, A0545) (B). BI: before induction. 032: total fraction of nucleocapsid protein from SARS-CoV-2 overexpression. 030, 033, 034: synthetic DNA constructs of SARS-CoV-2 nucleocapsid protein fused to OligoDOM®. MW: molecular weight markers. [Diagram 3] Efficacy of OV033 in a hamster challenge model. Hamsters were vaccinated twice, 4 weeks apart, with 50 μg of OVX033 by intramuscular (IM) or intranasal route (IN), or with NaCl as a negative control. Animals were challenged with 104 TCID50 of the B.1(D614G) SARS-COV-2 strain 4 weeks after the last vaccination. [A] Post-infection (pi) weight progression, [B] Lung virus titers 4 days post-infection, and [C] Area of pneumonia in the lungs 7 days post-infection. Statistical analysis: *p<0.05, **p<0.01 [Figure 4] Efficacy of OVX033 in a hamster challenge model with the B.1 strain of SARS-Cov-2. Hamsters were vaccinated twice, 4 weeks apart, with 50 μg or 100 μg of OVX033 by intramuscular (IM) or with NaCl as a negative control. Animals were challenged with 104 TCID50 of the B.1(D614G) SARS-COV-2 strain 4 weeks after the last vaccination. [A] Post-infection (pi) weight progression, [B] lung virus titers 4 days post-infection, and [C] pneumonia area in the lungs 7 days post-infection. Statistical analysis: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. [Diagram 5]Efficacy of OVX033 in a hamster challenge model with the delta strain of SARS-CoV-2. Hamsters were vaccinated twice, 4 weeks apart, by intramuscular route (IM) with 50 μg of OVX033 or NaCl as a negative control. Animals were challenged with 104 TCID50 of the B.1.617.2 SARS-COV-2 strain (delta) 4 weeks after the last vaccination. [A] Lung virus titers 4 days after infection, and [B] area of pneumonia in the lungs 7 days after infection. Statistical analysis: **p<0.01. [Figure 6] Efficacy of OV033 in a hamster challenge model with the Omicron strain of SARS-CoV-2. Hamsters were vaccinated twice, 4 weeks apart, by intramuscular route (IM) with 50 μg of OVX033 or NaCl as a negative control. Animals were challenged with 104 TCID50 of B.1.1.529 SARS-COV-2 strain (Omicron) 4 weeks after the last vaccination. [A] Lung virus titer 4 days after infection, [B] virus titer in nasal turbinates 7 days after infection, and [C] area of pneumonia in lungs 7 days after infection. Statistical analysis: **p<0.01. [Figure 7] Immunogenicity of OVX033 in hamsters. Hamsters were vaccinated twice, 4 weeks apart, by intramuscular route (IM) with 50 μg OVX033 or NaCl as a negative control. Animals were euthanized 4 weeks after the last vaccination and immune responses were characterized by ELISA and IFNγ ELISpot. [A] N-specific serum IgG antibody titers in serum of D56. [B] IFNγ ELISpot responses in spleen of D56. [C] IFNγ ELISpot responses in lung of D56. Statistical analysis: **p<0.01. [Figure 8] Mean number of NP-specific IFNγ spot-forming T cells (SFC / 2×105 PBMC) for each group (OVX032, OVX030, OVX30+IFA, OVX030+AdaVax) 8 days after the second vaccination. Statistics were performed using the Kruskal-Wallis test followed by Dunn's multiple comparison test. ***p<0.001.
[0025] [Mode for carrying out the invention] Detailed Description definition In order that this disclosure may be more readily understood, certain terms are defined at the beginning. Additional definitions are set forth throughout the detailed description.
[0026] The term "amino acid" refers to naturally occurring amino acids as well as unnatural amino acids (also referred to herein as "non-naturally occurring amino acids"), such as amino acid analogs and amino acid mimetics that function similarly to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those that are later modified, such as hydroxyproline, gamma-carboxyglutamic acid, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as a naturally occurring amino acid, such as an alpha carbon bonded to a hydrogen, a carboxyl group, an amino group, and an R group, such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refer to chemical compounds that have a structure that differs from the general chemical structure of an amino acid, but that function similarly to a naturally occurring amino acid. The terms "amino acid" and "amino acid residue" are used interchangeably throughout.
[0027] A substitution refers to the replacement of a naturally occurring amino acid with either another naturally occurring amino acid or a non-naturally occurring amino acid.
[0028] As used herein, the term "protein" refers to any organic compound made of amino acids arranged in one or more linear chains (also referred to as "polypeptides") and folded into a globular shape. The term "protein" includes proteinaceous substances or fusion proteins. The amino acids in such polypeptide chains may be linked together by peptide bonds between the carboxyl and amino groups of adjacent amino acid residues. The term "protein" further includes, but is not limited to, peptides, single-chain polypeptides, or any composite protein that is primarily composed of two or more chains of amino acids. The term "protein" further includes, but is not limited to, glycoproteins or other known post-translational modifications. The term "protein" further includes known natural or artificial chemical modifications of natural proteins, such as, but not limited to, glycosylation, PEGylation, HESylation, PASylation, etc., incorporation of non-natural amino acids, chemical conjugation, or amino acid modification for other molecules, etc.
[0029] The term "recombinant protein," as used herein, includes proteins that are prepared, expressed, produced, or isolated by recombinant means, such as fusion proteins isolated from a host cell, e.g., a transfectoma, that has been transformed to express the corresponding protein.
[0030] As used herein, the term "fusion protein" refers to a recombinant protein comprising at least one polypeptide chain obtained or obtainable by genetic fusion, e.g., by genetic fusion of at least two gene fragments encoding separate functional domains of distinct proteins. Protein fusions of the present disclosure include, for example, at least a coronavirus nucleocapsid N antigen and at least one other moiety, such as a carrier protein comprising a self-assembling polypeptide derived from the C4bp oligomerization domain and its positively charged tail, as described below.
[0031] As used herein, the term "antigenic" polypeptide includes immunogenic fragments and epitopes of a particular polypeptide (e.g., nucleocapsid N of a coronavirus strain) that are capable of inducing an immune response against such antigenic polypeptide (e.g., an N-specific immune response), at least when such antigenic polypeptide is fused to a carrier protein disclosed herein.
[0032] As used herein, the percent identity between two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps and the length of each gap that need to be introduced for optimal alignment of the two sequences (i.e., % identity = number of identical positions / total number of positions x 100). The comparison of sequences and determination of the percent identity between two sequences can be accomplished using a mathematical algorithm, as described below.
[0033] The percent identity between two amino acid sequences can be determined using the Needleman and Wunsch algorithm (NEEDLEMAN and Wunsch).
[0034] Percent identity between two nucleotide or amino acid sequences may also be determined using algorithms such as, for example, EMBOSS Needle (pairwise alignment; available at www.ebi.ac.uk, Rice et al., 2000 Trends Genet 16:276-277). For example, EMBOSS Needle may be used with a BLOSUM62 matrix, a "gap open penalty" of 10, a "gap extension penalty" of 0.5, a false "end gap penalty", an "end gap open penalty" of 10, and an "end gap extension penalty" of 0.5. In general, the "percent identity" is a function of the number of matched positions divided by the number of positions compared and multiplied by 100. For example, if 6 out of 10 sequence positions are identical between the two compared sequences after alignment, then the identity is 60%. The percent identity is typically determined over the entire length of the query sequence over which the analysis is performed. Two molecules that have the same primary amino acid or nucleic acid sequence are identical despite any chemical and / or biological modifications.
[0035] As used herein, the term "optimized" means that the nucleotide sequence has been modified to encode an amino acid sequence using codons that are preferred in the production cell or organism, typically a bacterial cell, such as an E. coli strain. An optimized nucleotide sequence has been engineered to retain completely or as much as possible of the amino acid sequence originally encoded by the starting nucleotide sequence. The amino acid sequence encoded by an optimized nucleotide sequence is also referred to as an optimized amino acid sequence.
[0036] As used herein, the term "subject" includes any human or non-human animal. The term "non-human animal" preferably includes mammals, such as non-human primates, sheep, dogs, cats, horses, etc.
[0037] As used herein, a "variant" of a polypeptide may be a naturally occurring or artificial mutant variant, typically obtained, for example, by amino acid substitution, deletion, or insertion, as compared to the corresponding native polypeptide. In certain embodiments, a variant may have a combination of amino acid deletions, insertions, or substitutions throughout the sequence of the variant, as compared to the parent polypeptide.
[0038] In the context of this disclosure, conservative substitutions include the following: Aliphatic residues I, L, V, and M Cycloalkenyl associated residues F, H, W, and Y Hydrophobic residues A, C, F, G, H, I, L, M, R, T, V, W, and Y Negatively charged residues D and E Polar residues C, D, E, H, K, N, Q, R, S, and T Positively charged residues H, K, and R Small residues A, C, D, G, N, P, S, T, and V Very small residues A, G, and S Residues A, C, D, E, G, H, K, N, Q, R, S, P involved in rotation, and residue T involved in formation Flexible residues Q, T, K, S, G, P, D, E, and R The amino acid sequence can be defined by substitutions within the classes of amino acids shown as follows:
[0039] A "functional variant" is a variant that retains the desired properties of the native polypeptide.
[0040] In preferred embodiments, a variant comprises an amino acid sequence that is at least 50%, 60%, 70%, 80%, 90%, or 95% identical to a native polypeptide sequence.
[0041] Thus, polypeptides containing substitutions, insertions and / or additions, deletions, and covalent modifications to a reference sequence, particularly to the nucleocapsid N fusion protein disclosed herein, are included within the scope of this disclosure. For example, sequence tags or amino acids, such as one or more lysines, can be added to the peptide sequence (e.g., at the N-terminus or C-terminus). Sequence tags can be used for peptide detection, purification, or localization. Lysines can be used to increase peptide solubility or to enable biotinylation. Alternatively, amino acid residues located at the carboxy- and amino-terminal regions of the amino acid sequence of a peptide or protein can be optionally deleted to result in a truncated sequence. Alternatively, certain amino acids (e.g., C-terminal or N-terminal residues) can be deleted depending on the use of the sequence, such as, for example, expression of the sequence as part of a larger sequence that is soluble or linked to a solid support.
[0042] As used herein, the term "coronavirus disease" refers to any disease caused by a coronavirus infection, in particular SARS (severe acute respiratory syndrome), MERS (Middle East respiratory syndrome), or preferably COVID-19 (coronavirus disease 2019), more particularly severe COVID-19.
[0043] As used herein, the term "prevention" or "preventing" in the context of disease refers to one or more of: (1) reducing the risk of experiencing or exhibiting a disease state or disorder or any symptom associated with a disease in an individual who may be exposed to such risk; and (2) reducing the risk of severe disease or the risk of exhibiting one or more severe symptoms of a disease; or (3) reducing viral shedding, thereby potentially reducing the transmission of the virus from one subject to another. In particular, with respect to the prevention of infectious disorders, the term "prevention" may refer to preventing infection by an infectious agent, inhibiting the replication of an infectious agent, reducing or eliminating any symptoms associated with a disease, reducing viral shedding, or reducing the severity and / or duration of one or more symptoms associated with an infection, or eradicating an infectious agent. As used herein, the term "protection" may be used interchangeably when referring to reducing the incidence of severe disease or the frequency of exhibiting one or more severe symptoms of a disease.
[0044] For example, in the context of coronavirus disease, severe coronavirus disease can refer to (i) an individual with an SpO2 of less than 94% in room air at sea level, an arterial blood oxygen pressure to inspired oxygen ratio (PaO2 / FiO2) of less than 300 mmHg, a respiratory rate of more than 30 breaths per minute, or pulmonary infiltration of more than 50%, and / or (ii) an individual with respiratory failure, septic shock, and / or multiple organ dysfunction. In some embodiments, the term "severe disease" with respect to coronavirus disease refers to an individual with respiratory deficiency symptoms requiring hospitalization.
[0045] Prevention or protection is determined in a group of subjects and may not apply to all individuals. Typically, prevention or protection can be determined in a randomized clinical trial compared to a control group.
[0046] Nucleocapsid N antigen As used herein, the term "nucleocapsid N antigen" or simply "N antigen" refers to any native coronavirus nucleocapsid N protein or antigenic variants thereof.
[0047] Natural coronavirus nucleocapsid N proteins include, but are not limited to, the nucleocapsids of any of the coronaviruses, particularly SARS-Cov1, MERS-Cov, and SARS-Cov2.
[0048] In some embodiments, the nucleocapsid antigen (N) is derived from a viral strain of SARS-Cov2, more specifically a SARS-Cov2 strain selected from the group consisting of the Wuhan (A), European (B.1), Alpha-UK (B.1.1.7), Beta South African (B.1.351), Gamma Brazil (P.1), Delta Indian (B.1.617.2) and Omicron strains.
[0049] In a specific embodiment, the nucleocapsid antigen (N) is an N antigen from a SARS-Cov2 strain, more specifically, the Wuhan (A) strain, comprising the polypeptide of SEQ ID NO:1.
[0050] In specific embodiments, the antigenic variant is a fragment of a coronavirus nucleocapsid antigen having at least 50, 100, 150, 200, 250, 300, 350, 400, 450, 490 consecutive amino acid residues of a wild-type coronavirus nucleocapsid of coronaviruses SARS-Cov1, MERS-Cov or SARS-Cov2, preferably from SEQ ID NO: 1. A fragment of a coronavirus nucleocapsid antigen is by definition at least one amino acid shorter than the corresponding full-length native coronavirus nucleocapsid, typically from SARS-Cov1, MERS-Cov or SARS-Cov2.
[0051] In specific embodiments, the antigenic variant of a coronavirus nucleocapsid antigen is an antigenic polypeptide variant having at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to the corresponding wild-type sequence of a coronavirus nucleocapsid, typically from SARS-Cov1, MERS-Cov, or preferably SARS-Cov2. Preferably, the antigenic variant of a coronavirus nucleocapsid antigen is an antigenic polypeptide variant having at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO:1.
[0052] In a particular embodiment, the variant differs from the corresponding coronavirus nucleocapsid native antigen by only amino acid substitutions at natural or non-natural amino acids, preferably only 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions at natural amino acids, especially when compared to the native SARS-Cov2 nucleocapsid antigen of SEQ ID NO: 1. In a specific embodiment, the variant is a mutant variant having 1, 2, or 3 amino acid substitutions at natural amino acids compared to the native SARS-Cov2 nucleocapsid antigen of SEQ ID NO: 1. In a more specific embodiment, the variant is a natural variant (i.e., a variant found in nature that does not result from human recombinant technology) having only 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions compared to the SARS-Cov2 nucleocapsid antigen of SEQ ID NO: 1, especially when compared to the native SARS-Cov2 nucleocapsid antigen of SEQ ID NO: 1.
[0053] In more specific embodiments, the amino acid sequence of said mutant variants may differ from a native coronavirus nucleocapsid antigen by mostly conservative amino acid substitutions, e.g., at least 10, e.g., at least 9, 8, 7, 6, 5, 4, 3, 2, or 1 of the substitutions in the variant are conservative amino acid residue substitutions.
[0054] More conservative substitution classes include valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine. Conservation of hydropathicity index / hydrophilic properties and residue weight / size of any coronavirus nucleocapsid antigen, typically compared to a parent polypeptide of SEQ ID NO: 1, can also be substantially retained in the variant mutant polypeptide.
[0055] In a specific embodiment, the mutant variant comprises a polypeptide that is identical to SEQ ID NO:1 except for one, two, or three amino acid residues that are replaced with another naturally occurring amino acid by a conservative amino acid substitution as defined above.
[0056] In specific embodiments, the variant of the coronavirus nucleocapsid antigen is, e.g., www.IEDB.org The variants of coronavirus nucleocapsids do not contain any mutations compared to the parent polypeptide of SEQ ID NO: 1 in epitopes recognized by the human immune system as described in the IEDB database (Immune Epitope Database), accessible at: http: / / www.iedb.org / . In a specific embodiment, the variants of coronavirus nucleocapsids do not contain any mutations compared to the parent polypeptide of SEQ ID NO: 1 in any of the amino acid residues that are conserved between the nucleocapsid of SEQ ID NO: 1 (from the Wuhan (A) strain) and the nucleocapsids of the corresponding nucleocapsid amino acid sequences of Europe (B.1), alpha-UK (B.1.1.7), beta South Africa (B.1.351), gamma Brazil (P.1) delta India (B.1.617.2) and Omicron.
[0057] As used herein, a "conserved amino acid residue" corresponds to an amino acid residue that is identical between the nucleocapsid of the Wuhan (A) strain and the nucleocapsid of the European (B.1), alpha-UK (B.1.1.7), beta South African (B.1.351), gamma Brazilian (P.1) delta Indian (B.1.617.2) and Omicron nucleocapsid amino acid sequences when aligned using a standard sequence-protein alignment, such as using the BLAST algorithm.
[0058] Carrier Proteins As used herein, the term "carrier protein" generally refers to a protein to which an antigen is conjugated or fused, thereby making the antigen more immunogenic. The function of a carrier protein is to increase the immunogenicity of the antigen to which it is conjugated or fused.
[0059] The carrier protein for use in the fusion protein comprises a self-assembling polypeptide derived from the C4bp oligomerization domain and a positively charged tail. The complement inhibitor C4 binding protein (C4bp) is an abundant plasma protein first found in mice. The natural function of C4bp is to inhibit the classical and lectin pathways of complement activation. The last exon of the C4bp alpha chain gene encodes the only domain in the protein that does not belong to the complement regulatory protein family. This non-complement regulatory protein domain contains 57 amino acid residues in humans and 54 amino acid residues in mice, and is necessary and sufficient for the oligomerization of C4bp. When fused to an antigen, the self-assembling polypeptide has also been found to be necessary and sufficient for the oligomerization of the resulting fusion protein.
[0060] International applications PCT / IB2004 / 002717 and PCT / EP03 / 08926 describe the use of mammalian C4bp oligomerization domains to enhance the immunogenicity of antigens in mammals. WO 2007 / 062819 further describes the chicken species C4bp oligomerization domain and variants thereof.
[0061] In a preferred embodiment, to minimize autoimmune responses, the self-assembling polypeptide has less than 30%, preferably less than 20%, identity to the human C4bp oligomerization domain.
[0062] In particular, in a specific embodiment, said self-assembling polypeptide derived from a C4bp oligomerization domain comprises or consists essentially of SEQ ID NO:2.
[0063] In specific embodiments, a functional variant of the self-assembling polypeptide has at least 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO:2.
[0064] Functional variants may include any variant that has one or more amino acid additions, deletions, and / or substitutions compared to SEQ ID NO:2 and that retains the self-assembly properties of the polypeptide of SEQ ID NO:2.
[0065] In certain embodiments, the variant differs from SEQ ID NO:2 by only amino acid substitutions at natural or unnatural amino acids, preferably by only 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions at natural amino acids. In specific embodiments, the variant is a mutant variant having 1, 2, or 3 amino acid substitutions at natural amino acids compared to SEQ ID NO:2.
[0066] In more specific embodiments, the amino acid sequence of the mutant variant may differ from the self-assembling polypeptide of SEQ ID NO:2 by mostly conservative amino acid substitutions, e.g., at least 10, e.g., at least 9, 8, 7, 6, 5, 4, 3, 2, or 1 of the substitutions in the variant are conservative amino acid residue substitutions.
[0067] The carrier protein further comprises a C-terminal tail consisting of a positively charged peptide. The C-terminal tail is preferably a peptide consisting of 6-10 amino acids, at least 50% of which are positively charged amino acids. Positively charged amino acids include arginine or lysine. Examples of such positively charged peptides are disclosed in WO 2014 / 090905 and WO 2014 / 147087.
[0068] In a preferred embodiment, the positively charged tail comprises the sequence ZXBBBBZ (SEQ ID NO:3), where (i) Z is absent or any amino acid, (ii) X is any amino acid, and (iii) B is arginine or lysine, and preferably, the positively charged tail comprises or consists essentially of the sequence of SEQ ID NO:4.
[0069] In a more preferred embodiment, the carrier protein consists essentially of an OVX313 polypeptide corresponding to the polypeptide of SEQ ID NO:5.
[0070] In a specific embodiment, the carrier protein is a functional variant of the OVX313 polypeptide of SEQ ID NO:5 having at least 70%, 80%, or more preferably at least 90% identity to SEQ ID NO:5.
[0071] In another embodiment, the carrier protein is a functional variant of an OVX313 polypeptide of SEQ ID NO:5 that differs from SEQ ID NO:5 by only 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids due to amino acid substitutions. In another embodiment, the carrier protein is a functional variant of an OVX313 polypeptide of SEQ ID NO:5 that differs from SEQ ID NO:5 by only 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids due to conservative amino acid substitutions.
[0072] N fusion proteins The fusion protein for use according to the present disclosure comprises: (i) a coronavirus nucleocapsid antigen as defined above; and (ii) a carrier protein as defined above, comprising a self-assembling polypeptide derived from a C4bp oligomerization domain and a positively charged tail; Includes.
[0073] The resulting fusion protein with the nucleoprotein antigen is referred to hereafter as the "N fusion protein" for ease of reading.
[0074] In a specific embodiment, the carrier protein is fused to the nucleocapsid antigen at the C-terminus, optionally via a peptide linker. The peptide linker can be any short peptide linker commonly used for fusion proteins. Preferred peptide linkers include glycine-serine linkers, such as the dipeptide gly-ser, or gly-ser-ser-ser, or (gly-ser-ser-ser)n, where n is an integer between 1 and 4.
[0075] In a specific embodiment, said N fusion proteins form heptameric particles after self-assembly.
[0076] In a specific embodiment, the N fusion protein forms particles after self-assembly with a diameter of less than 100 nm, for example between 5 and 100 nm, more specifically between 10 and 100 nm. The diameter of the particles can be measured, for example, by dynamic light scattering (DLS). DLS measures the hydrodynamic diameter of particles in the size range of approximately 0.3 nm to 10 μm. DLS measurements are very sensitive to temperature and dispersion medium viscosity. Therefore, the temperature needs to be kept constant at 25° C. and the viscosity of the dispersion medium needs to be known.
[0077] In a specific embodiment, the N fusion protein comprises a nucleocapsid N selected from a SARS-Cov2 strain, preferably selected from the group consisting of Wuhan (A), European (B.1), Alpha-UK (B.1.1.7), Beta South African (B.1.351), Gamma Brazil (P.1), Delta Indian (B.1.617.2) and Omicron. In a preferred embodiment, the N fusion protein comprises a nucleocapsid N selected from the Wuhan (A) strain.
[0078] In a more preferred embodiment, said N fusion protein consists essentially of an OVX033 polypeptide corresponding to the polypeptide of SEQ ID NO:6, more preferably encoded by SEQ ID NO:11.
[0079] In a specific embodiment, the N fusion protein is a functional variant of an OVX033 polypeptide having at least 70%, 80%, or more preferably at least 90% identity to SEQ ID NO:6.
[0080] In another embodiment, the N fusion protein is a functional variant of an OVX033 polypeptide of SEQ ID NO: 6 that differs from SEQ ID NO: 6 by only 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids due to amino acid substitutions. In another embodiment, the N fusion protein is a functional variant of an OVX033 polypeptide that differs from SEQ ID NO: 6 by only 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids due to conservative amino acid substitutions.
[0081] The inventors have surprisingly found that such N fusion proteins, particularly when produced in bacterial expression systems, such as E. coli expression systems, have excellent immunogenic properties, particularly with respect to protecting against coronavirus disease.
[0082] In specific embodiments, the N-fusion proteins of the present disclosure do not exhibit N-glycosylation typical of glycoproteins produced in mammalian cells (e.g., CHO or human cell lines). In more specific embodiments, the N-fusion proteins are not glycosylated. In other specific embodiments, the N-fusion proteins of the present disclosure are obtainable or obtained from a bacterial expression system, such as an E. coli expression system.
[0083] Methods for preparing N fusion proteins N-fusion proteins for use according to the present disclosure can be prepared by any conventional method for preparing recombinant proteins, using nucleic acid molecules encoding said N-fusion proteins whose nucleotide sequences are readily obtained using the genetic code and, optionally, taking into account codon bias according to the host cell type.
[0084] Preferred examples of nucleotide sequences that can be used to prepare N fusion proteins are nucleotide sequences that typically encode the amino acid sequences of SEQ ID NOs: 1 to 6 listed in Tables 2 and 3.
[0085] Nucleic acid molecules can be derived from amino acid sequences and optimized for protein expression in prokaryotic cells, such as E. coli cells.
[0086] In a more preferred embodiment, said N fusion protein is prepared in a bacterial cell expression system using an optimized coding nucleic acid sequence of SEQ ID NO: 11. The inventors have surprisingly found that the resulting N fusion protein is produced with such an optimized sequence in a suitable quality and yield compared to other nucleotide sequences.
[0087] The nucleic acid may be present in whole cells, in a cell lysate, or may be in a partially purified or substantially pure form. A nucleic acid is "isolated" or "substantially pure" when it has been purified from other cellular components or other contaminants, e.g., other cellular nucleic acids or proteins, by standard techniques, including alkaline / SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis, and other techniques well known in the art. The nucleic acid of the present disclosure may be, for example, DNA or RNA, and may or may not contain intron sequences. In one embodiment, the nucleic acid may be present in a vector, e.g., a recombinant plasmid vector.
[0088] Nucleic acids can be obtained using standard molecular biology techniques. After the DNA fragments encoding the nucleoprotein antigens are obtained, these DNA fragments can be further manipulated by standard recombinant DNA techniques. In these manipulations, for example, the DNA fragment encoding the nucleocapsid antigen can be operatively linked to another DNA molecule, for example a fragment encoding a carrier protein, and optionally a linker.
[0089] The term "operably linked", as used in the above context, is intended to mean that two DNA fragments are functionally linked, e.g., such that the amino acid sequences encoded by the two DNA fragments remain in frame or that a protein is expressed under the control of a desired promoter.
[0090] The N fusion proteins of the disclosure (particularly OVX033) can then be produced in host cell transfectomas, for example, using a combination of recombinant DNA techniques and gene transfection methods well known in the art.
[0091] For example, to express an N fusion protein (typically OVX033), a corresponding fragment thereof, DNA encoding a partial or full-length recombinant protein can be obtained by standard molecular biological or biochemical techniques (e.g., DNA chemical synthesis, PCR amplification, or cDNA cloning), and the DNA can be inserted into an expression vector such that the gene is operably linked to transcriptional and translational control sequences.
[0092] In the above context, the term "operably linked" is intended to mean that the coding polypeptide sequence is ligated into a vector such that transcriptional and translational control sequences within the vector perform their intended function of regulating the transcription and translation of the recombinant N fusion protein. Expression vectors and expression control sequences are selected to be compatible with the expression host cell used. Protein-encoding genes are inserted into expression vectors by standard techniques.
[0093] The recombinant expression vector can encode a signal peptide that facilitates secretion of the recombinant fusion protein from a host cell. The N fusion protein-encoding gene can be cloned into the vector such that the signal peptide is linked in-frame to the amino terminus of the recombinant protein. The signal peptide can be the native signal peptide of C4bp or a heterologous signal peptide (i.e., a signal peptide from a non-C4bp protein). In a specific embodiment, the signal peptide is a methionine amino acid.
[0094] In addition to the N fusion protein coding sequence, the recombinant expression vector disclosed herein may carry a regulatory sequence that controls the expression of the recombinant fusion protein in a host cell. The term "regulatory sequence" is intended to include promoters, enhancers, and other expression control elements (e.g., polyadenylation signals) that control the transcription or translation of a protein-encoding gene. It will be understood by those skilled in the art that the design of the expression vector, including the selection of the regulatory sequence, may depend on factors such as the choice of the host cell to be transformed, the level of expression of the protein desired, and the like.
[0095] In a specific embodiment, the expression vector comprises the coding sequence of SEQ ID NO:11 operably linked to a bacterial promoter for expression in a bacterial host cell.
[0096] Regulatory sequences for mammalian host cell expression include promoters and / or enhancers derived from viral elements that direct high levels of protein expression in mammalian cells, such as promoters and / or enhancers derived from cytomegalovirus (CMV), Simian Virus 40 (SV40), adenovirus (e.g., the adenovirus major late promoter (AdMLP)), and polyoma. Alternatively, non-viral regulatory sequences may be used, such as the ubiquitin promoter or P-globin promoter. Additionally, regulatory elements composed of sequences from different sources may be used, such as the SRa promoter system, which contains sequences from the SV40 early promoter and the long terminal repeat of human T-cell leukemia virus type 1.
[0097] In addition to the N fusion protein coding sequence and regulatory sequences, the recombinant expression vector of the present disclosure may carry additional sequences, such as sequences that regulate replication of the vector in a host cell (e.g., origins of replication) and selectable marker genes. The selectable marker genes facilitate the selection of host cells into which the vector has been introduced. For example, selectable marker genes confer resistance to antibiotics (in bacterial expression systems) or drugs (e.g., G418).
[0098] For expression of the N fusion protein, the expression vector(s) encoding the recombinant protein are transfected into a host cell by standard techniques. The various forms of the term "transfection" are intended to encompass a wide variety of techniques commonly used for the introduction of foreign DNA into prokaryotic or eukaryotic host cells, such as electroporation, calcium phosphate precipitation, DEAE-dextran transfection, etc. It is theoretically possible to express the proteins of the present disclosure in either prokaryotic or eukaryotic host cells.
[0099] Expression of the N protein can be carried out in prokaryotic cells, such as E. coli host cells. The N fusion protein can then be recovered by lysis of bacterial cells and further purification using standard purification procedures. In a specific embodiment, the N fusion protein is produced according to a method similar to that disclosed in DelCampo 2021 (Frontiers in Immunology, doi:10 / 3389 / fimm.2021.678483).
[0100] In a specific embodiment, the present disclosure relates to a bacterial host cell, typically an E. coli host cell, for the production of an N fusion protein comprising the coding sequence of SEQ ID NO:11 or an expression vector comprising the coding sequence of SEQ ID NO:11.
[0101] immunogenic composition In another aspect, the disclosure provides compositions, e.g., immunogenic compositions, containing an N-fusion protein described in the previous section and one or more pharma- ceutically acceptable excipients.
[0102] The immunogenic compositions include any aqueous vehicle suitable for parenteral, intranasal, intramuscular, or subcutaneous administration (e.g., by intramuscular injection). These aqueous vehicles may in particular be isotonic sterile saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride, etc., or mixtures of such salts).
[0103] In a specific embodiment, the N-fusion protein comprises at least 400 amino acid residues, such as between 400 and 600 amino acid residues, such as between 540 and 560 amino acid residues, and optionally the N-fusion protein forms a particle in the immunogenic composition as disclosed herein, having a diameter of between 5 and 100 nm, such as between 10 and 100 nm.
[0104] For example, the immunogenic composition is an aqueous composition comprising a polypeptide of SEQ ID NO: 6 (OVX033) or a variant having at least 70%, 80%, preferably at least 90%, or at least 95% identity to SEQ ID NO: 6, formulated together with one or more pharma- ceutically acceptable excipients.
[0105] In a specific embodiment, the immunogenic composition is an aqueous composition comprising a polypeptide of SEQ ID NO: 6 (OVX033), wherein the polypeptide is obtained from the coding sequence of SEQ ID NO: 11 and is non-glycosylated.
[0106] In a preferred embodiment, the immunogenic composition is an aqueous composition comprising a polypeptide of SEQ ID NO: 6 (OVX033), said polypeptide being obtained from the coding sequence of SEQ ID NO: 11 and obtained from a bacterial expression system, typically an E. coli host cell.
[0107] In a specific embodiment, the immunogenic composition provides a fusion protein comprising nucleocapsid N selected from a SARS-Cov2 strain selected from the group consisting of Wuhan (A), European (B.1), Alpha-UK (B.1.1.7), Beta South African (B.1.351), Gamma Brazil (P.1), Delta Indian (B.1.617.2) and Omicron.
[0108] In a specific embodiment, the immunogenic composition provides multiple fusion proteins from different SARS-Cov2 strains, particularly but not necessarily selected from the group consisting of Wuhan (A), European (B.1), Alpha-UK (B.1.1.7), Beta South African (B.1.351), Gamma Brazil (P.1), Delta Indian (B.1.617.2) and Omicron.
[0109] In specific embodiments, the immunogenic composition may further comprise one or more of the following excipients, e.g., buffers, salts, osmolytes, antioxidants, and surfactants or other agents to prevent protein loss and / or protein aggregation on the vial surface.
[0110] The form of the pharmaceutical composition, the route of administration, the dosage and the regimen will of course depend on the condition to be treated, the severity of the disease, the age, weight, and sex of the patient, etc.
[0111] In a preferred embodiment, the composition is formulated for intramuscular administration.
[0112] In some embodiments, the immunogenic composition is formulated in an effective amount of N fusion protein (typically OVX033) to generate an antigen N-specific immune response in a human subject with one or two doses administered to the subject, preferably via the intramuscular route.
[0113] For intramuscular administration, for example, the composition is an aqueous solution that may be suitably buffered as necessary, and a liquid diluent that is first rendered at least isotonic with sufficient salt or sugar. In this regard, sterile aqueous media that may be used will be known to those skilled in the art in light of this disclosure. Examples of formulations of injection solutions are provided in Remington: The Science and Practice of Pharmacy, 23rd Edition, 2020. Some variation in dosage may be made depending on the condition of the subject being treated. Further specific examples of formulations are provided in the examples, particularly for use with OVX033.
[0114] In a specific embodiment, the immunogenic composition further comprises an additional coronavirus antigen, typically selected from the spike S protein or the membrane M protein.
[0115] In a specific embodiment, the immunogenic composition further comprises a nucleocapsid N antigen as the only coronavirus antigen, in particular, the immunogenic composition does not comprise an additional coronavirus antigen selected from the spike S protein or the membrane M protein.
[0116] In a specific embodiment, the immunogenic composition further comprises one or more adjuvants selected from the group consisting of an aluminum salt (e.g., aluminum oxide, aluminum hydroxide, or aluminum phosphate), squalene, or a liposome-based adjuvant, optionally in combination with a Toll-like receptor (TLR) agonist or a saponin.
[0117] In another specific embodiment, the immunogenic composition does not include any adjuvant.
[0118] In a specific embodiment, the immunogenic compositions are formulated as ready-to-use sterile injectable solutions.
[0119] Sterile injectable solutions are prepared by incorporating the active compound, ie, N-fusion protein, in the required amount in the appropriate solvent containing various other ingredients, as required, followed by filtered sterilization.
[0120] Methods of Use of Immunogenic Compositions of N and NP Fusion Proteins The N fusion proteins described in the previous section (particularly OVX033, more particularly the N fusion protein obtained from SEQ ID NO: 11 in a bacterial host cell) and immunogenic compositions thereof are useful as vaccines in the prevention of coronavirus diseases, particularly COVID-19, typically for protection against severe COVID-19, in human subjects in need thereof.
[0121] Thus, the present disclosure provides compositions (e.g., the immunogenic compositions described in the previous section), methods, kits, and reagents for the prevention of coronavirus diseases in humans and other mammals. The N-fusion proteins or immunogenic compositions disclosed herein can be used as prophylactic agents. The N-fusion proteins or immunogenic compositions disclosed herein may be used in medicines for preventing and / or protecting against coronavirus diseases, particularly COVID-19, more particularly for protecting against severe COVID-19.
[0122] In an exemplary embodiment, the N fusion protein or immunogenic composition of the present disclosure is used to provide prophylactic protection against coronavirus disease, particularly SARS-Cov2 disease, such as COVID-19, typically to protect against severe COVID-19. Prophylactic protection from coronavirus can be achieved following administration of an immunogenic amount of the composition of the present disclosure, typically having one or more immunogenic doses of OVX033. The immunogenic composition can be administered once, twice, three times, or four or more times.
[0123] In some embodiments, an N fusion protein or immunogenic composition of the disclosure can be used in a method of preventing a coronavirus infection in a subject, the method comprising administering to the subject at least one immunogenic dose of an N fusion protein or composition provided herein, typically a composition that includes OVX033 as an antigenic determinant.
[0124] In some embodiments, an N fusion protein or immunogenic composition of the disclosure can be used as a method for inhibiting a primary coronavirus infection in a subject, the method comprising administering to the subject at least one immunogenic dose of an N fusion protein or composition provided herein, typically a composition that includes OVX033 as an antigenic determinant.
[0125] In some embodiments, the N-fusion proteins or immunogenic compositions of the present disclosure can be used as a method of reducing the incidence of coronavirus disease, typically severe coronavirus disease, in a subject, comprising at least administering to the subject an immunogenic dose of an N-fusion protein or composition provided herein, typically a composition comprising OVX033 as an antigenic determinant. In some embodiments, the N-fusion proteins or immunogenic compositions of the present disclosure can be used as a method of protecting against coronavirus disease, typically severe coronavirus disease, such as severe COVID-19, in a subject, comprising at least administering to the subject an immunogenic dose of an N-fusion protein or composition provided herein, typically a composition comprising OVX033 as an antigenic determinant.
[0126] As used herein, the term "severe COVID-19" means Moderate Illness: Individuals who demonstrate evidence of lower respiratory tract disease during clinical evaluation or imaging and have an oxygen saturation (SpO2) of 94% or greater in room air at sea level. Severe illness: Individuals with SpO2 less than 94% in room air at sea level, a ratio of arterial blood oxygen pressure to inspired oxygen concentration (PaO2 / FiO2) less than 300 mmHg, a respiratory rate greater than 30 breaths / min, or greater than 50% pulmonary infiltrates. Severe illness: individuals with respiratory failure, septic shock, and / or multiple organ dysfunction It refers to either:
[0127] In some embodiments, the term "severe COVID-19" refers to COVID-19 with respiratory deficiency symptoms requiring hospitalization.
[0128] In some embodiments, the N-fusion protein or immunogenic composition of the present disclosure can be used as a method of protecting a subject against one or more severe symptoms of COVID-19, comprising at least administering to the subject an immunogenic dose of an N-fusion protein or composition provided herein, typically a composition comprising OVX033 as an antigenic determinant. In some embodiments, the N-fusion protein or immunogenic composition of the present disclosure can be used as a method of inhibiting coronavirus transmission from a first subject infected with coronavirus to a second subject not infected with coronavirus, comprising administering to the first subject and the second subject at least one immunogenic dose of an N-fusion protein or composition provided herein, typically a composition comprising OVX033 as an antigenic determinant.
[0129] As used herein, the term "immunogenic dose" refers to an amount that is sufficient to induce an antigen N-specific immune response in a subject when such amount is administered once or multiple times to a subject in need thereof.
[0130] Some embodiments of the present disclosure provide a method of inducing an antigen N-specific immune response in a subject, comprising administering to the subject any of the immunogenic compositions provided herein, preferably an immunogenic composition comprising OVX033, in an amount effective to generate an N-specific immune response. In some embodiments, the antigen N-specific immune response comprises a total T cell response (particularly a CD4+ or CD8+ N-specific T cell response) and / or a B cell response (specific anti-N immunoglobulin response).
[0131] Some embodiments of the present disclosure provide a method of inducing an antigen N-specific cross-reactive immune response in a subject, comprising administering to the subject any of the immunogenic compositions provided herein (preferably an immunogenic composition having a Wuhan A SARS-Cov2 strain, more preferably OVX033), in an amount effective to generate a cross-reactive N-specific immune response, particularly against other coronavirus strains, such as European (B.1), Alpha-UK (B.1.1.7), Beta South African (B.1.351), Gamma Brazilian (P.1), Delta Indian (B.1.617.2), Omicron, SARS-Cov1, and MERS-CoV.
[0132] Some embodiments of the present disclosure provide a method of inducing an antigen N-specific cross-reactive immune response in a subject, comprising administering to the subject any of the immunogenic compositions provided herein (preferably an immunogenic composition having a Wuhan A SARS-Cov2 strain, more preferably OVX033), in an amount effective to generate a cross-reactive N-specific immune response, particularly against other SARS-Cov2 strains, such as European (B.1), Alpha-UK (B.1.1.7), Beta South African (B.1.351), Gamma Brazilian (P.1), Delta Indian (B.1.617.2), and Omicron.
[0133] In some embodiments, the antigen-N specific immune response comprises a total T cell response (particularly a CD4+ or CD8+ N specific T cell response) and / or a B cell response (a specific anti-N immunoglobulin response).
[0134] In some embodiments, a method for generating an antigen N-specific immune response comprises administering to a subject a single dose of an immunogenic composition of the disclosure (typically having, for example, SEQ ID NO:11 and / or OVX033 obtained from a bacterial expression system, for example, an E. coli host cell).
[0135] In some embodiments, the immunogenic composition (typically comprising OVX033) is administered to the subject by intradermal injection, intramuscular injection, or intranasal administration. In a preferred embodiment, the immunogenic composition (typically comprising OVX033) is administered to the subject by intramuscular injection.
[0136] The data presented in the Examples demonstrate significant enhanced protection against coronavirus disease using immunogenic compositions specifically with OVX033 in hamsters, as well as cross-reactive immune responses against other coronavirus infections, including other SARS-Cov2 strains.
[0137] In some embodiments, the effective amount of the N fusion protein (typically OVX033) is one or more doses of 10 μg to 1000 μg, 50 μg to 1000 μg, or more.
[0138] In some embodiments, the immunogenic composition for use as a vaccine (typically comprising OVX033) protects a subject against severe COVID-19.
[0139] In some embodiments, the immunogenic composition for use as a vaccine (typically comprising OVX033) protects a subject against one or more severe symptoms of coronavirus disease, such as lung injury, respiratory failure, septic shock, and / or multiple organ dysfunction.
[0140] In some embodiments, an immunogenic composition having an N fusion protein of SARS-Cov2 nucleocapsid N antigen for use as a vaccine (typically comprising OVX033) provides a cross-reactive immune response (e.g., nucleocapsid N-specific CD4+ and / or CD8+ T cell response, anti-nucleocapsid N IgG (antibody response)) against other coronaviruses selected from the group consisting of European (B.1), alpha-UK (B.1.1.7), beta South African (B.1.351), gamma Brazilian (P.1), delta Indian (B.1.617.2), Omicron, SARS-Cov1, and MERS-CoV.
[0141] In some embodiments, an immunogenic composition having an N fusion protein of SARS-Cov2 nucleocapsid N antigen for use as a vaccine (typically comprising OVX033) provides a cross-reactive immune response (e.g., nucleocapsid N-specific CD4+ and / or CD8+ T cell response, anti-nucleocapsid N IgG (antibody response)) against other SARS-Cov2 strains selected from the group consisting of European (B.1), alpha-UK (B.1.1.7), beta South African (B.1.351), gamma Brazilian (P.1), delta Indian (B.1.617.2), and Omicron.
[0142] In some embodiments, the immunogenic composition for use as a vaccine (typically comprising OVX033) immunizes a subject against coronavirus disease from one or more of the SARS-Cov2 strains selected from the group consisting of Wuhan (A), European (B.1), Alpha-UK (B.1.1.7), Beta South African (B.1.351), Gamma Brazil (P.1), Delta Indian (B.1.617.2) and Omicron strains.
[0143] In some embodiments, the immunogenic composition for use as a vaccine (typically comprising OVX033) provides cross-protection against one or more of the coronavirus symptoms from other coronavirus diseases, for example protection against one or more of the severe coronavirus symptoms such as lung damage, respiratory failure, septic shock, and / or multiple organ dysfunction, more specifically from coronavirus disease caused by a coronavirus infection selected from the group consisting of European (B.1), Alpha-UK (B.1.1.7), Beta South African (B.1.351), Gamma Brazilian (P.1), Delta Indian (B.1.617.2), Omicron, SARS-Cov1, and MERS-CoV, more specifically from the group consisting of European B.1, Delta, Omicron and / or Beta.
[0144] In some embodiments, the subject has been exposed to a coronavirus (e.g., one or more of a SARS-Cov2 strain selected from the group consisting of Wuhan (A), European (B.1), Alpha-UK (B.1.1.7), Beta South African (B.1.351), Gamma Brazilian (P.1), Delta Indian (B.1.617.2), and Omicron strains), the subject is infected with a coronavirus, or the subject is at risk for infection by a coronavirus.
[0145] In other embodiments, the subject is at risk of developing severe Covid-19. Risk factors include, but are not limited to, (listed alphabetically): age (risk increases with each decade after age 50), cancer, cardiovascular disease, chronic kidney disease, chronic pulmonary disease, diabetes, immunocompromised conditions or taking immunosuppressive medications, obesity (body mass index > 30), pregnancy, and sickle cell disease.
[0146] In some embodiments, the subject is either (i) an elderly subject (e.g., over 65, 70, or 80 years of age), (ii) a pregnant subject, (iii) an immunocompromised subject, or (iv) a child (e.g., under 18 years of age, or under 16, 14, 12, 10, 8, 6, 4, 2, or 2 years of age).
[0147] In other embodiments, the immunogenic composition is administered simultaneously or sequentially in combination with a second coronavirus vaccine, preferably selected from coronavirus vaccines comprising protein spike or an antigenic fragment thereof.
[0148] In a specific embodiment, the immunogenic composition is administered simultaneously or sequentially in combination with an mRNA coronavirus vaccine, typically an mRNA coronavirus comprising an mRNA encoding the SARS-Cov2 spike protein or an antigenic fragment thereof, e.g., selected from the group consisting of the COMIRNATY vaccine (Pfizer-BioNTech; BNT162b2 mRNA) or the SPIKEVAX COVID-19 vaccine (Moderna, mRNA-1273 SARS-CoV-2).
[0149] As used herein, the terms "combination," "concomitant administration," or "co-administration" refer to the combined administration of at least two active ingredients (e.g., immunogenic compositions), where a first immunogenic composition comprising an N-fusion protein as disclosed herein is administered simultaneously with a second vaccine or immunogenic composition or separately within a time interval to the same subject in need thereof, said time interval allowing the combined active ingredients to exhibit a cooperative or synergistic effect on the immune response or protection against a coronavirus, typically Covid-19. Although simultaneous or separate delivery methods within a time interval are included within the scope described herein, it is not intended to imply that the immunogenic compositions must be administered simultaneously and / or formulated together for delivery. The terms "combination," "concomitant administration," or "co-administration" are also intended to encompass regimes in which the active (immunogenic) agents are not necessarily administered by the same route of administration.
[0150] In a specific embodiment, the other coronavirus vaccine (e.g., an mRNA vaccine comprising an mRNA encoding SARS-Cov2 spike protein or antigenic fragment) is first administered prior to the immunogenic composition of the present disclosure, typically within a time interval comprised between 1 month and 3 months prior to administration of the immunogenic composition. In a specific embodiment, the practitioner can adjust the order of administration of the vaccines to ideally provide a simultaneous immune response between the other vaccine (e.g., an mRNA vaccine) and the N fusion protein vaccine, resulting in a synergistic effect on the immune or protective response.
[0151] The present disclosure is further illustrated by the following embodiments, examples and figures, which, however, should not be construed as limiting the scope of the present disclosure in any way.
[0152] Specific embodiments E1. An immunogenic composition for use as a vaccine for the prevention of a coronavirus disease, particularly COVID-19, typically for protection against severe COVID-19, in a human subject in need thereof, said immunogenic composition comprising a fusion protein, said fusion protein comprising: (i) a coronavirus nucleocapsid N antigen, preferably a SARS-Cov2 nucleocapsid N antigen, to which it is fused (ii) a carrier protein comprising a self-assembling polypeptide derived from the C4bp oligomerization domain and a positively charged tail; An immunogenic composition comprising:
[0153] E2. The immunogenic composition for use according to E1, wherein said fusion protein is non-glycosylated.
[0154] E3. The immunogenic composition for use according to E1 or E2, wherein the fusion protein is obtainable from a bacterial expression system, such as an E. coli expression system.
[0155] E4. The immunogenic composition for use according to any one of E1-E3, wherein the carrier protein is fused to the nucleocapsid N antigen at the C-terminus, optionally via a glycine-serine linker.
[0156] E5. The immunogenic composition for use according to any one of E1-E4, wherein the fusion protein forms a heptameric protein after self-assembly.
[0157] E6. The immunogenic composition for use according to any one of E1-E5, wherein the SARS-Cov2 nucleocapsid N antigen comprises at least one nucleocapsid N antigen from a SARS-Cov2 strain, e.g., the SARS-Cov2 nucleocapsid N antigen consists essentially of the nucleocapsid N protein of the SARS-Cov2 Wuhan (A) strain [P0DTC9(NCAP_SARS2), severe acute respiratory syndrome coronavirus 2 (2019-nCoV)].
[0158] E7. The nucleocapsid N antigen (i) a polypeptide of SEQ ID NO: 1, or (ii) an antigenic polypeptide variant having at least 90% identity to SEQ ID NO:1; An immunogenic composition for use according to any one of E1 to E6, comprising:
[0159] E8. The immunogenic composition for use according to any one of E1 to E7, wherein the self-assembling polypeptide derived from the C4bp oligomerization domain comprises SEQ ID NO:2, or a functional variant having at least 90% identity to SEQ ID NO:2.
[0160] E9. The immunogenic composition for use of any one of E1-E8, wherein the positively charged tail comprises the sequence ZXBBBBZ (SEQ ID NO:3), where (i) Z is absent or any amino acid, (ii) X is any amino acid, and (iii) B is arginine or lysine, preferably, wherein the positively charged tail comprises the sequence of SEQ ID NO:4.
[0161] E10. The immunogenic composition for use according to any one of E1-E9, wherein the carrier protein consists essentially of SEQ ID NO:5, or the carrier protein is a functional variant of SEQ ID NO:5 having at least 90% identity to SEQ ID NO:5.
[0162] E11. The immunogenic composition for use according to any one of E1-E10, wherein the fusion protein comprises or consists essentially of SEQ ID NO:6, or is a functional variant of SEQ ID NO:6 having at least 90% identity to SEQ ID NO:6.
[0163] E12. The immunogenic composition for use according to E11, wherein said fusion protein is encoded by SEQ ID NO:11.
[0164] E13. The immunogenic composition for use according to any one of E1-E12, wherein said immunogenic composition is administered via the intramuscular route.
[0165] E14. The immunogenic composition for use according to any one of E1-E14, wherein said immunogenic composition does not comprise a SARS-Cov2 spike S antigen, preferably wherein a SARS-Cov2 nucleocapsid N antigen is the only SARS-Cov2 antigenic determinant in the composition.
[0166] E15. The immunogenic composition for use according to any one of E1-E14, wherein said use provides protection against one or more of the following: nucleocapsid N-specific total T cell response, nucleocapsid N-specific CD4+ and / or CD8+ T cell response, anti-nucleocapsid N IgG (antibody response), and / or protection against one or more of the following coronavirus symptoms, for example protection against one or more of the following severe coronavirus symptoms such as lung damage, respiratory failure, septic shock, and / or multiple organ dysfunction, more particularly protection against coronavirus disease resulting from infection with a coronavirus strain selected from the group consisting of Wuhan (A), European (B.1), Alpha-UK (B.1.1.7), Beta South African (B.1.351), Gamma Brazil (P.1), Delta Indian (B.1.617.2), Omicron, SARS-Cov1, and MERS-CoV, more particularly protection from coronavirus disease resulting from infection with a coronavirus strain selected from the group consisting of European B.1, Delta, Omicron and / or Beta.
[0167] E16. The immunogenic composition for use according to any one of claims E1-E15, wherein the SARS-Cov2 nucleocapsid N antigen is selected from the Wuhan (A) strain, and wherein the use provides a nucleocapsid N-specific total T cell response, a nucleocapsid N-specific CD4+ / CD8+ T cell response, an anti-nucleocapsid N IgG (antibody response), and / or cross-protection from coronavirus disease resulting from infection with a coronavirus strain selected from the group consisting of European (B.1), alpha-UK (B.1.1.7), beta South African (B.1.351), gamma Brazilian (P.1), delta Indian (B.1.617.2), Omicron, SARS-Cov1, and MERS-CoV, more particularly selected from the group consisting of European (B.1), delta, omicron and / or beta strains.
[0168] E17. (i) The SARS-Cov2 nucleocapsid N antigen and the (ii) a carrier protein comprising a self-assembling polypeptide derived from the C4bp oligomerization domain and a positively charged tail; A fusion protein comprising:
[0169] E18. The fusion protein as described in E17, which is not glycosylated.
[0170] E19. A fusion protein according to E17 or E18, obtainable from a bacterial expression system, such as an E. coli expression system.
[0171] E20. The fusion protein of any one of E17-E19, wherein the carrier protein is fused at the C-terminus to a nucleocapsid N antigen, optionally via a glycine-serine linker.
[0172] E21. The fusion protein according to any one of E17 to E20, which forms a heptameric protein after self-assembly.
[0173] E22. The fusion protein of any one of E17 to E21, wherein the SARS-Cov2 nucleocapsid N antigen comprises at least one nucleocapsid N antigen from the SARS-Cov2 Wuhan (A) strain, typically strain [P0DTC9(NCAP_SARS2), severe acute respiratory syndrome coronavirus 2 (2019-nCoV)].
[0174] E23. The nucleocapsid N antigen, (i) a polypeptide of SEQ ID NO: 1, or (ii) an antigenic polypeptide variant having at least 90% identity to SEQ ID NO:1; The fusion protein according to any one of E17 to E22, comprising:
[0175] E24. The fusion protein according to any one of E17 to E23, wherein the self-assembling polypeptide derived from the C4bp oligomerization domain comprises SEQ ID NO:2 or a functional variant having at least 90% identity to SEQ ID NO:2.
[0176] E25. The fusion protein of any one of E17 to E24, wherein the positively charged tail comprises the sequence ZXBBBBZ (SEQ ID NO:3), where (i) Z is absent or any amino acid, (ii) X is any amino acid, and (iii) B is arginine or lysine, preferably wherein the positively charged tail comprises the sequence of SEQ ID NO:4.
[0177] E26. The fusion protein of any one of E17 to E25, wherein the carrier protein consists essentially of SEQ ID NO:5, or wherein the carrier protein is a functional variant of SEQ ID NO:5 having at least 90% identity to SEQ ID NO:5.
[0178] E27. The fusion protein of any one of E17 to E26, comprising or consisting essentially of SEQ ID NO:6, or being a functional variant of SEQ ID NO:6 having at least 90% identity to SEQ ID NO:6.
[0179] E28. The fusion protein described in E27, encoded by SEQ ID NO:11.
[0180] E29. A nucleic acid encoding a fusion protein as defined in any one of E17 to E28.
[0181] An expression vector for producing a fusion protein as defined in any one of E17 to E28, comprising the nucleic acid as defined in E30.E29.
[0182] E31. A host cell for producing a fusion protein as defined in any one of E17 to E28, comprising an expression vector as defined in E30.
[0183] E32. A host cell according to E31, which is a bacterial, preferably an E. coli host cell.
[0184] E33. An immunogenic composition comprising the fusion protein according to any one of E17 to E28 and one or more pharma- ceutically acceptable excipients.
[0185] E34. The immunogenic composition of E33 formulated for intramuscular administration.
[0186] E35. A method for producing a fusion protein according to any one of E17 to E28, comprising: (i) culturing a host cell according to E31 or E32 under conditions for synthesis of the fusion protein by said host cell; (ii) recovering the fusion protein; (iii) optionally, purifying the fusion protein; The method includes:
[0187] E36. A method for inducing an immune response against a coronavirus, typically SARS-Cov2, or for preventing a coronavirus disease, in particular COVID-19 or severe COVID-19, in a human subject in need thereof, comprising: (i) a nucleocapsid N antigen, preferably a SARS-Cov2 N antigen, to which it is fused (ii) a carrier protein comprising a self-assembling polypeptide derived from the C4bp oligomerization domain and a positively charged tail; Administering an immunogenic amount of a composition comprising a fusion protein comprising:
[0188] E37. The method of E36, wherein said fusion protein is non-glycosylated.
[0189] E38. The method of E36 or E37, wherein the fusion protein is obtainable from a bacterial expression system, such as an E. coli expression system.
[0190] E39. The method of any one of E36 to E38, wherein the carrier protein is fused at the C-terminus to the nucleocapsid N antigen, optionally via a glycine-serine linker.
[0191] E40. The method according to any one of E36 to E39, wherein said fusion protein forms a heptameric particle after self-assembly.
[0192] E41. The method of any one of E36 to E40, wherein the SARS-Cov2 nucleocapsid N antigen comprises at least one nucleocapsid N antigen from a SARS-Cov2 strain, e.g., the SARS-Cov2 nucleocapsid N antigen consists essentially of the nucleocapsid N protein of the SARS-Cov2 Wuhan (A) strain [P0DTC9(NCAP_SARS2), severe acute respiratory syndrome coronavirus 2 (2019-nCoV)].
[0193] E42. The nucleocapsid N antigen is (i) a polypeptide of SEQ ID NO: 1, or (ii) an antigenic polypeptide variant having at least 90% identity to SEQ ID NO:1; The method according to any one of E36 to E41, comprising:
[0194] E43. The method according to any one of E36 to E42, wherein the self-assembling polypeptide derived from the C4bp oligomerization domain comprises SEQ ID NO:2 or a functional variant having at least 90% identity to SEQ ID NO:2.
[0195] E44. The method of any one of E36 to E43, wherein the positively charged tail comprises the sequence ZXBBBBZ (SEQ ID NO:3), where (i) Z is absent or any amino acid, (ii) X is any amino acid, and (iii) B is arginine or lysine, preferably, wherein the positively charged tail comprises the sequence of SEQ ID NO:4.
[0196] E45. The method of any one of E36 to E44, wherein the carrier protein consists essentially of SEQ ID NO:5, or the carrier protein is a functional variant of SEQ ID NO:5 having at least 90% identity to SEQ ID NO:5.
[0197] E46. The method of any one of E36 to E45, wherein the fusion protein comprises or consists essentially of SEQ ID NO:6, or is a functional variant of SEQ ID NO:6 having at least 90% identity to SEQ ID NO:6.
[0198] E47. The method of E46, wherein the fusion protein is encoded by SEQ ID NO:11.
[0199] E48. The method of any one of E36-E47, wherein said immunogenic composition is administered by intramuscular injection.
[0200] E49. The method of any one of E36 to E48, wherein said immunogenic composition does not include a SARS-Cov2 spike antigen, preferably, SARS-Cov2 nucleocapsid N antigen is the only SARS-Cov2 antigenic determinant in the composition.
[0201] E50. The method of any one of E36 to E49, providing protection or cross-protection against one or more of a nucleocapsid N specific total T cell response, a nucleocapsid N specific CD4+ T cell response, an anti-nucleocapsid N IgG (antibody response), and / or a coronavirus symptom, such as protection against one or more of a severe coronavirus symptom such as lung damage, respiratory failure, septic shock, and / or multiple organ dysfunction, more specifically protection or cross-protection from a coronavirus disease resulting from infection with a coronavirus strain selected from the group consisting of Wuhan (A), European (B.1), Alpha-UK (B.1.1.7), Beta South African (B.1.351), Gamma Brazil (P.1), Delta Indian (B.1.617.2), Omicron, SARS-Cov1, and MERS-CoV, more specifically selected from the group consisting of European B.1, Delta, Omicron and / or Beta.
[0202] E51. The method of any one of E36 to E49, wherein the SARS-Cov2 nucleocapsid N antigen is from the Wuhan (A) strain and the method results in a cross-reactive immune response against a coronavirus infection selected from the group consisting of European (B.1), alpha-UK (B.1.1.7), beta South African (B.1.351), gamma Brazilian (P.1), delta Indian (B.1.617.2), Omicron, SARS-Cov1, and MERS-CoV, more particularly selected from the group consisting of European B.1, delta, omicron and / or beta.
[0203] E52. The method of any one of E36 to E49, wherein the SARS-Cov2 nucleocapsid N antigen is from the Wuhan A strain, and wherein the method provides cross-protection against one or more of the coronavirus symptoms from other coronavirus diseases, for example protection against one or more of the severe coronavirus symptoms such as lung damage, respiratory failure, septic shock, and / or multiple organ dysfunction, more specifically from coronavirus disease caused by a coronavirus infection selected from the group consisting of European (B.1), Alpha-UK (B.1.1.7), Beta South African (B.1.351), Gamma Brazilian (P.1), Delta Indian (B.1.617.2), Omicron, SARS-Cov1, and MERS-CoV, more specifically from the group consisting of European B.1, Delta, Omicron and / or Beta.
[0204] [Example] Example 1: OVX030 exhibits a truncated form that is not suitable for vaccine development To generate the vaccine of the present disclosure, DNA constructs were obtained by DNA synthesis of E. coli codon-optimized genes. First, two constructs were synthesized, one construct (SEQ ID NO: 12) encoding OVX030 and another construct (SEQ ID NO: 13) encoding OVX031, both of which consisted of N of SARS-CoV2 [P0DTC9 (NCAP_SARS2), severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)] and N of SARS-CoV [P59595 (NCAP_SARS), severe acute respiratory syndrome coronavirus (SARS-CoV)] fused with OVX313, respectively. Both constructs were cloned into E. coli expression vectors with IPTG-inducible T5 promoter.
[0205] Protein expression of OVX030 and OVX031 encoding constructs using E. coli BL21 (New England BioLabs, #C2530H) was able to reach high expression levels even though the production was performed at 25° C. and in the presence of 30 μg / mL kanamycin. The OVX030 encoding construct was initially chosen because its expression level was slightly higher than that of OVX031 and it is composed of N from SARS-CoV2.
[0206] Small batches of OVX030 were made and purified initially by an ion exchange chromatography purification step followed by size exclusion chromatography. These batches were subjected to a small set of analyses (concentration (A280), protein purity on SDS PAGE, identity by Western blotting, and monomeric full mass by LC-MS). LC-MS analysis of the batch showed an apparent mass of 51959.8 Da (Δ0.3 Da from theoretical MW) in line with expectations.
[0207] In contrast, SDS PAGE and Western blot analysis (using anti-nucleocapsid antibodies) highlighted a truncated form of OVX030 that could not be removed during the purification steps (red narrow area, Figure 1), a finding that was clearly inconsistent with the characteristics expected of a candidate vaccine.
[0208] Example 2: Selection of a codon-optimized sequence encoding OVX033 suitable for vaccine development Three other constructs were then synthesized. The first construct (SEQ ID NO: 14) was synthesized, encoding N of SARS-CoV2. OVX032 was made to serve as a control protein without the OVX313 C-terminal domain. The remaining two constructs (encoding OVX033 and OVX034, respectively) are two codon-optimized variant sequences of the construct encoding N from SARS-CoV2 fused with OVX313. The first construct encoding OVX033 (SEQ ID NO: 11) was a completely novel E. coli optimized gene obtained by DNA synthesis. The second gene construct encoding OVX034 (SEQ ID NO: 15) was homologous to the gene construct encoding OVX032 for the DNA sequence corresponding to the nucleocapsid.
[0209] The OVX033 construct expressed in E. coli according to the parameters previously defined for OVX030 and OVX031 exhibits high protein expression levels with a substantial reduction in expression of the truncated forms (detected in the construct encoding OVX030). Figure 2 shows the protein expression levels of OVX033 and OVX034 compared to OVX030.
[0210] Thus, the OVX033 vaccine candidate is a recombinant protein encoded by SEQ ID NO: 11 expressed in E. coli cells, and the subunit of the OVX033 vaccine candidate consists of the nucleocapsid (N) of SARS-CoV2 [P0DTC9(NCAP_SARS2), Severe Acute Respiratory Syndrome Coronavirus 2 (2019-nCoV) (SARS-CoV-2)] fused with OVX313 (Oligodom®). The OVX033 vaccine candidate is composed of 475 amino acids.
[0211] Through a combination of disulfide bonds, hydrogen bonds, salt bridges, and numerous hydrophobic interactions, the OVX313 C-terminal domain allows the fused protein to spontaneously heptamerize, thus forming a heptameric recombinant protein containing seven copies of each subunit and with a molecular weight (MW) of 363.7 kDa (i.e., 51.96 kDa x 7) and an isoelectric point (pI) of 10.03.
[0212] Example 3: Preclinical Data Using OVX033 in a Hamster Protection Study 3.1 Research #1 OVX033, used in the first hamster protection study, was characterized as follows:
[0213] [Table 1]
[0214] OVX033 was formulated at 1 mg / mL and the study arms were as follows:
[0215] [Table 2]
[0216] Ten hamsters per group were vaccinated intranasally (IN) or intramuscularly (IM) with OVX033 as described above on D0 and D28 (4 weeks apart). On D56, i.e. 28 days after the last vaccination, 10 4 TCID 50 Animals were infected intranasally with the Sars-CoV-2 strain (Europe (B.1)). Five hamsters were sacrificed on D+4 post-infection (D60) and the remaining hamsters (5 per group) on D+7 post-infection (D63). Hamsters' weights were monitored daily from the day of infection. On D60 and D63, viral loads were analyzed in lungs, throat swabs and nasal turbinates of all sacrificed hamsters. Histopathological analysis was performed on lungs from all sacrificed hamsters.
[0217] The key results obtained during the study are summarized below: Regarding weight loss measured 7 days after Sars-CoV-2 infection, OVX033 IM, but not OVX033 IN, protected hamsters from weight loss after Sars-CoV-2 infection, with significant differences from the NaCl negative control group observed on D4, D5, D6 and D7 after infection (see Figure 3A ; statistical analysis was performed using two-way ANOVA followed by Dunnett's multiple comparison test); A significant reduction in the viral load measured in the lungs was observed only in OVX033 IM (see Figure 3B ; statistical analysis: Mann-Whitney test between the OVX033-treated group and the NaCl group); In the lungs, a significant reduction in lung injury was observed in OVX033 IM at D7 post-infection (see FIG. 3C, histopathology results; statistical analysis: t-test between OVX033-treated group and NaCl group).
[0218] 3.2 Research #2 OVX033, used in the second hamster protection study, was characterized as follows:
[0219] [Table 3]
[0220] [Table 4]
[0221] Ten hamsters per group were vaccinated on D0 and D28 (4 weeks apart) with the formulations described above. On D56, i.e. 28 days after the last vaccination, 10 4 TCID 50Animals were infected intranasally with the Sars-CoV-2 strain (Europe (B.1)). Five hamsters were sacrificed on D+4 post-infection (D60) and the remaining hamsters (5 per group) on D+7 post-infection (D63). Hamsters' weights were monitored daily from the day of infection. On D60 and D63, viral loads were analyzed in lungs, throat swabs and nasal turbinates of all sacrificed hamsters. Histopathological analysis was performed on lungs from all sacrificed hamsters.
[0222] Key results obtained during the study: Again, a significant reduction in the amount of virus measured in the lungs was observed in the treatment groups (OVX033 50 and 100 μg) (Figure 4B, statistical analysis: Mann-Whitney test between the OVX033 treatment group and the NaCl group). In the lungs, a significant reduction in lung injury was observed at D7 post-infection with OVX033 at 50 μg and 100 μg (FIG. 4C, histopathology results, statistical analysis: t-test between OVX033-treated group and NaCl group).
[0223] With regard to weight loss measured 7 days after SARS-CoV-2 infection, OVX033 at 50 μg or 100 μg protected hamsters from weight loss after SARS-CoV-2 infection, with significant differences from the NaCl negative control group observed on D4, D5, D6 and D7 post-infection (Figure 4A, statistical analysis was performed using two-way ANOVA followed by Dunnett's multiple comparison test).
[0224] 3.3 Research #3 OVX033, used in the third hamster protection study, was characterized as follows:
[0225] [Table 5] OVX033 was formulated at 0.5 mg / mL:
[0226] [Table 6]
[0227] Twelve hamsters per group were vaccinated intramuscularly (IM) with OVX033 as described above on D0 and D28 (4 weeks apart). On D56, i.e. 28 days after the last vaccination, 10 4 TCID 50 Animals were infected intranasally with the Sars-CoV-2 strain (Delta, B.1.617.2) of hamsters bred in the USA. Six hamsters were sacrificed on D+4 (D60) post-infection, and the remaining hamsters (6 per group) were sacrificed on D+7 (D63) post-infection. The weights of the hamsters were monitored daily from the day of infection. On D60 and D63, the viral load was analyzed in lungs, throat swabs and nasal turbinates of all sacrificed hamsters. Histopathological analysis was performed on lungs from all sacrificed hamsters.
[0228] The key results obtained during the study are summarized below: A significant reduction in viral load measured by RT-qPCR in the lungs was observed after vaccination with OVX033 (see Figure 5A ; statistical analysis: Mann-Whitney test between the OVX033-treated group and the NaCl group); In the lungs, a significant reduction in lung injury was observed at D7 post-infection in OVX033 (see Figure 5B, histopathology results, statistical analysis: Mann-Whitney test between the OVX033-treated group and the NaCl group).
[0229] 3.4 Research #4 OVX033, used in the fourth hamster protection study, was characterized as follows:
[0230] [Table 7] OVX033 was formulated at 0.5 mg / mL:
[0231] [Table 8]
[0232] Twelve hamsters per group were vaccinated intramuscularly (IM) with OVX033 as described above on D0 and D28 (4 weeks apart). On D56, i.e. 28 days after the last vaccination, 10 4 TCID 50 Animals were infected intranasally with the Sars-CoV-2 strain (Omicron, B.1.1.529). Six hamsters were sacrificed on D+4 (D60) post-infection and the remaining hamsters (6 per group) on D+7 (D63) post-infection. Hamster weights were monitored daily from the day of infection. On D60 and D63, viral loads were analyzed in lungs, throat swabs and nasal turbinates of all sacrificed hamsters. Histopathological analysis was performed on lungs from all sacrificed hamsters.
[0233] The key results obtained during the study are summarized below: A significant reduction in viral load measured by RT-qPCR in the lungs was observed after vaccination with OVX033 (see Figure 6A ; statistical analysis: Mann-Whitney test between the OVX033-treated group and the NaCl group); A significant reduction in viral load measured by RT-qPCR in nasal turbinates was observed 7 days after vaccination with OVX033 (see Figure 6B ; statistical analysis: Mann-Whitney test between the OVX033-treated group and the NaCl group); In the lungs, a significant reduction in lung injury was observed in OVX033 IM at D7 post-infection (see Figure 6C, histopathology results, statistical analysis: Mann-Whitney test between the OVX033-treated group and the NaCl group).
[0234] Example 4: Immunogenicity of OVX033 in hamsters OVX033, used in this hamster immunogenicity study, is characterized as follows:
[0235] [Table 9] OVX033 was formulated at 0.5 mg / mL:
[0236] [Table 10]
[0237] Five hamsters per group were vaccinated intramuscularly (IM) with OVX033 as described above on DO and D28 (4 weeks apart). Serum was collected from retro-orbital bleeds on DO and D56 (sacrifice) for anti-N IgG analysis by ELISA. On D56, 28 days after the last vaccination, animals were euthanized, lungs and spleens were harvested, cells were isolated and analyzed by IFNγ ELISpot 18 hours after stimulation with an 11aa overlapping 15-mer nucleoprotein peptide pool (from the Wuhan SARS-CoV-2 strain, Swiss-Prot ID: P0DTC9).
[0238] The key results obtained during the study are summarized below: High levels of anti-N-specific serum IgG antibodies were detected in sera after two vaccinations with OVX033 (see FIG. 7A, individual values and mean±95% CI). Significant IFNγ T cell-specific responses were detected in the spleen and lungs (see Figures 7B and 7C; statistical analysis: Mann-Whitney test between the OVX033-treated group and the NaCl group).
[0239] Example 5: Comparative study in mice of OVX030 (fused N-OVX313) versus OVX032 (unfused N antigen) showing IFNγ T cell specific responses in lung cells Materials and Methods: OVX030 is a fusion of the SARS-Cov2 N antigen with OVX313, described in Example 1 (encoded by SEQ ID NO: 12). OVX032 is the SARS-Cov2 N antigen disclosed in Example 2 (encoded by SEQ ID NO: 14).
[0240] Five groups of five C57BL6 mice were immunized with one of the following five regimens on days 0 and 28: (i) OVX032(N), (ii) OVX030(N-OVX313), (iii) OVX030(N-OVX313)+incomplete Freund's adjuvant (IFA), (iv) OVX030(N-OVX313)+MF59 adjuvant (AddaVax), or (v) buffer. Mice were sacrificed 8 days after vaccination for evaluation of immune responses.
[0241] result: In lung cells, OVX030 induces a cellular response, as shown in Figure 8. OVX032, which is antigen N alone, resulted in a significantly lower IFNγ cellular response than OVX030 (N-OVX313), and although the adjuvant tends to reduce the response, no statistical difference was observed.
[0242] Example 6: Sequences useful in practicing the invention
[0243] [Table 11]
[0244] [Table 12] TIFF2024545462000013.tif176149 TIFF2024545462000014.tif56149 TIFF2024545462000015.tif196149 TIFF2024545462000016.tif208149 TIFF2024545462000017.tif196149 TIFF2024545462000018.tif176149 TIFF2024545462000019.tif196149
Claims
1. 1. An immunogenic composition for use as a vaccine for the prevention of a coronavirus disease, particularly COVID-19, and more particularly for protection against severe COVID-19, in a human subject in need thereof, said immunogenic composition comprising a fusion protein, said fusion protein comprising: (i) SARS-Cov2 nucleocapsid N antigen and its fusion (ii) a carrier protein comprising a self-assembling polypeptide derived from the C4bp oligomerization domain and a positively charged tail; An immunogenic composition comprising:
2. The immunogenic composition for use according to claim 1 , wherein the fusion protein is non-glycosylated.
3. 3. The immunogenic composition for use according to claim 1 or 2, wherein the fusion protein is obtainable from a bacterial expression system, such as an E. coli expression system.
4. The immunogenic composition for use according to any one of claims 1 to 3, wherein the carrier protein is fused to the nucleocapsid N antigen at its C-terminus, optionally via a glycine-serine linker.
5. The immunogenic composition for use according to any one of claims 1 to 4, wherein the fusion protein forms a heptameric protein after self-assembly.
6. 6. The immunogenic composition for use according to any one of claims 1 to 5, wherein said SARS-Cov2 nucleocapsid N antigen comprises at least one nucleocapsid N antigen from a SARS-Cov2 strain, for example, said SARS-Cov2 nucleocapsid N antigen essentially consists of the nucleocapsid N protein of SARS-Cov2 Wuhan (A) strain [P0DTC9 (NCAP_SARS2), severe acute respiratory syndrome coronavirus 2 (2019-nCoV)].
7. The nucleocapsid N antigen is (i) a polypeptide of SEQ ID NO: 1, or (ii) an antigenic polypeptide variant having at least 90% identity to SEQ ID NO:1; An immunogenic composition for use according to any one of claims 1 to 6, comprising:
8. The immunogenic composition for use according to any one of claims 1 to 7, wherein the self-assembling polypeptide derived from the C4bp oligomerization domain comprises SEQ ID NO:2 or a functional variant having at least 90% identity to SEQ ID NO:
2.
9. 9. The immunogenic composition for use according to any one of claims 1 to 8, wherein said positively charged tail comprises the sequence ZXBBBBZ (SEQ ID NO:3), where (i) Z is absent or is any amino acid, (ii) X is any amino acid, and (iii) B is arginine or lysine, preferably wherein said positively charged tail comprises the sequence of SEQ ID NO:
4.
10. 10. The immunogenic composition for use according to any one of claims 1 to 9, wherein the carrier protein consists essentially of SEQ ID NO:5 or the carrier protein is a functional variant of SEQ ID NO:5 having at least 90% identity to SEQ ID NO:
5.
11. 11. The immunogenic composition for use according to any one of claims 1 to 10, wherein the fusion protein comprises or consists essentially of SEQ ID NO:6, or is a functional variant of SEQ ID NO:6 having at least 90% identity to SEQ ID NO:
6.
12. The immunogenic composition for use according to claim 11, wherein the fusion protein is encoded by SEQ ID NO:
11.
13. The immunogenic composition for use according to any one of claims 1 to 12, wherein said immunogenic composition is administered via the intramuscular route.
14. 14. The immunogenic composition for use according to any one of claims 1 to 13, wherein said use provides protection against one or more of the following: nucleocapsid N specific total T cell response, nucleocapsid N specific CD4+ / CD8+ T cell response, anti-nucleocapsid N IgG (antibody response), and / or protection against one or more of the coronavirus symptoms, for example protection against one or more of the severe coronavirus symptoms such as lung damage, respiratory failure, septic shock, and / or multiple organ dysfunction, more particularly protection against coronavirus diseases caused by coronavirus strains selected from the group consisting of Wuhan (A), European (B.1), alpha-UK (B.1.1.7), beta South African (B.1.351), gamma Brazilian (P.1), delta Indian (B.1.617.2), omicron, SARS-Cov1, and MERS-CoV, more particularly protection against coronavirus diseases caused by coronavirus strains selected from the group consisting of European B.1, delta, omicron and / or beta strains.
15. The SARS-Cov2 nucleocapsid N antigen is selected from the Wuhan (A) strain, and the use comprises: (i) a cross-reactive immune response against a coronavirus infection selected from the group consisting of European (B.1), alpha-UK (B.1.1.7), beta South African (B.1.351), gamma Brazilian (P.1), delta Indian (B.1.617.2), omicron, SARS-Cov1, and MERS-CoV, more particularly selected from the group consisting of European (B.1), delta, omicron and / or beta strains, such as a total T cell response specific for nucleocapsid N, a CD4+ / CD8+ T cell response specific for nucleocapsid N, an anti-nucleocapsid N IgG (antibody response), and / or (ii) cross-protection against coronavirus diseases caused by coronavirus infections selected from the group consisting of European (B.1), alpha-UK (B.1.1.7), beta South African (B.1.351), gamma Brazilian (P.1), delta Indian (B.1.617.2), omicron, SARS-Cov1, and MERS-CoV, more particularly selected from the group consisting of European (B.1), delta, omicron and / or beta strains; The immunogenic composition for use according to any one of claims 1 to 13, which results in
16. 16. The immunogenic composition for use according to any one of claims 1 to 15, administered simultaneously or sequentially in combination with a second coronavirus vaccine comprising the protein spike or an antigenic fragment thereof, such as an mRNA vaccine comprising mRNA encoding the SARS-Cov2 protein spike or an antigenic fragment thereof, preferably selected from the Comirnaty vaccine (Pfizer-BioNTech; BNT162b2 mRNA) or the SpikeBax COVID-19 vaccine (Moderna, mRNA-1273 SARS-CoV-2).
